Repros Therapeutics Inc. (NASDAQ:RPRX) shares saw an uptick in trading volume on Tuesday . 1,252,343 shares changed hands during mid-day trading, an increase of 55% from the previous session’s volume of 806,506 shares.The stock last traded at $0.35 and had previously closed at $0.31.

Separately, Laidlaw lowered Repros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, July 21st.

The company has a 50-day moving average of $0.32 and a 200 day moving average of $0.69. The stock’s market capitalization is $13.17 million.

Repros Therapeutics (NASDAQ:RPRX) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.14. The firm had revenue of $0.01 million during the quarter. Repros Therapeutics had a negative return on equity of 412.64% and a negative net margin of 56,062.07%. Equities research analysts expect that Repros Therapeutics Inc. will post ($1.07) earnings per share for the current year.

A hedge fund recently raised its stake in Repros Therapeutics stock. Renaissance Technologies LLC grew its stake in Repros Therapeutics Inc. (NASDAQ:RPRX) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 727,113 shares of the biotechnology company’s stock after purchasing an additional 10,700 shares during the period. Renaissance Technologies LLC owned approximately 2.73% of Repros Therapeutics worth $873,000 as of its most recent filing with the Securities and Exchange Commission. 14.52% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Receive News & Stock Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related stocks with our FREE daily email newsletter.